Promoting apoptosis as a strategy for cancer drug discovery (Q36292878)

13 August 2017

1 reference

title

Promoting apoptosis as a strategy for cancer drug discovery (English)

1 reference

13 August 2017

0 references

1 reference

Stephen W Fesik

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 November 2005

1 reference

13 August 2017

published in

Nature Reviews Cancer

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

13 August 2017

page(s)

876-885

1 reference

Apoptosis in the pathogenesis and treatment of disease

13 August 2017

cites work

1 reference

Cell death: critical control points

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

From bench to clinic with apoptosis-based therapeutic agents

31 March 2020

1 reference

Apoptosis by death factor

31 March 2020

1 reference

Biochemical pathways of caspase activation during apoptosis

31 March 2020

1 reference

Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs

31 March 2020

1 reference

X-linked IAP is a direct inhibitor of cell-death proteases

31 March 2020

1 reference

Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition

31 March 2020

1 reference

Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins

31 March 2020

1 reference

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

31 March 2020

1 reference

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

31 March 2020

1 reference

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

31 March 2020

1 reference

Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation

31 March 2020

1 reference

Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity

31 March 2020

1 reference

Targeting death receptors in cancer with Apo2L/TRAIL.

31 March 2020

1 reference

Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4

31 March 2020

1 reference

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

31 March 2020

1 reference

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

31 March 2020

1 reference

Engineering antibodies for therapy

31 March 2020

1 reference

Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo

31 March 2020

1 reference

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

31 March 2020

1 reference

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

31 March 2020

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

31 March 2020

1 reference

Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy

31 March 2020

1 reference

Safety and antitumor activity of recombinant soluble Apo2 ligand

31 March 2020

1 reference

Apo2L/TRAIL and its death and decoy receptors

31 March 2020

1 reference

Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis.

31 March 2020

1 reference

Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

31 March 2020

1 reference

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis

31 March 2020

1 reference

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

31 March 2020

1 reference

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

31 March 2020

1 reference

TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

31 March 2020

1 reference

Bcl-2-family proteins: the role of the BH3 domain in apoptosis

31 March 2020

1 reference

BH3-Only proteins-essential initiators of apoptotic cell death

31 March 2020

1 reference

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

31 March 2020

1 reference

Structural biology of the Bcl-2 family of proteins

31 March 2020

1 reference

Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis

31 March 2020

1 reference

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

31 March 2020

1 reference

The role of Bcl-2 family members in tumorigenesis

31 March 2020

1 reference

Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation

31 March 2020

1 reference

The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining

31 March 2020

1 reference

Expression of Bcl-2 family of proteins in fresh myeloma cells.

31 March 2020

1 reference

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

31 March 2020

1 reference

Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma

31 March 2020

1 reference

Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma

31 March 2020

1 reference

Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer.

31 March 2020

1 reference

Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study

31 March 2020

1 reference

Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer

31 March 2020

1 reference

Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis

31 March 2020

1 reference

c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients

31 March 2020

1 reference

bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining

31 March 2020

1 reference

Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival

31 March 2020

1 reference

Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance

31 March 2020

1 reference

bcl-2 protein expression is associated with better prognosis in colorectal cancer

31 March 2020

1 reference

Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2.

31 March 2020

1 reference

Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer

31 March 2020

1 reference

bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer

31 March 2020

1 reference

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

31 March 2020

1 reference

Antisense therapy for cancer

31 March 2020

1 reference

Lessons learnt from Genasense's failure

31 March 2020

1 reference

Antisense and/or immunostimulatory oligonucleotide therapeutics

31 March 2020

1 reference

Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases

31 March 2020

1 reference

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

31 March 2020

1 reference

Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry

31 March 2020

1 reference

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

31 March 2020

1 reference

Identification of chelerythrine as an inhibitor of BclXL function

31 March 2020

1 reference

Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2

31 March 2020

1 reference

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

31 March 2020

1 reference

Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins

31 March 2020

1 reference

(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance

31 March 2020

1 reference

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

31 March 2020

1 reference

Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening

31 March 2020

1 reference

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

31 March 2020

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP

31 March 2020

1 reference

A single BIR domain of XIAP sufficient for inhibiting caspases

31 March 2020

1 reference

Structural basis for the inhibition of caspase-3 by XIAP

31 March 2020

1 reference

NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP

31 March 2020

1 reference

Mechanism of XIAP-mediated inhibition of caspase-9

31 March 2020

1 reference

Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

31 March 2020

1 reference

Structural basis of IAP recognition by Smac/DIABLO

31 March 2020

1 reference

The inhibitors of apoptosis (IAPs) and their emerging role in cancer

31 March 2020

1 reference

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ

31 March 2020

1 reference

Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.

31 March 2020

1 reference

Structure-based design of potent, conformationally constrained Smac mimetics

31 March 2020

1 reference

Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics.

31 March 2020

1 reference

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer

31 March 2020

1 reference

Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction

31 March 2020

1 reference

Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database

31 March 2020

1 reference

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

31 March 2020

1 reference

Non-peptidic small molecule inhibitors of XIAP

31 March 2020

1 reference

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

31 March 2020

1 reference

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

31 March 2020

1 reference

Survivin, versatile modulation of cell division and apoptosis in cancer

31 March 2020

1 reference

MDM2--master regulator of the p53 tumor suppressor protein

31 March 2020

1 reference

Therapeutic exploitation of the p53 pathway

31 March 2020

1 reference

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

31 March 2020

1 reference

Molecular characterization of the hdm2-p53 interaction

31 March 2020

1 reference

Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

31 March 2020

1 reference

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure

31 March 2020

1 reference

A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells

31 March 2020

1 reference

1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

31 March 2020

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment

31 March 2020

1 reference

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

31 March 2020

1 reference

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

31 March 2020

1 reference

The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136

31 March 2020

1 reference

Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1

31 March 2020

1 reference

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

31 March 2020

1 reference

Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling.

31 March 2020

1 reference

Direct control of the Forkhead transcription factor AFX by protein kinase B

31 March 2020

1 reference

Transformation of interleukin-3-dependent cells without participation of Stat5/bcl-xL: cooperation of akt with raf/erk leads to p65 nuclear factor kappaB-mediated antiapoptosis involving c-IAP2.

31 March 2020

1 reference

Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action

31 March 2020

1 reference

The Akt pathway: molecular targets for anti-cancer drug development

31 March 2020

1 reference

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

31 March 2020

1 reference

Targeting the molecular target of rapamycin (mTOR).

31 March 2020

1 reference

The proteasome: a suitable antineoplastic target

31 March 2020

1 reference

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

31 March 2020

1 reference

RETRACTED: Inactivation of MAP kinase signalling in Myc transformed cells and rescue by LiCl inhibition of GSK3.

31 March 2020

1 reference

9 February 2024

https://opencitations.net/index/api/v1/citations/10.1186/1476-4598-4-13

Identifiers

DOI

10.1038/NRC1736

1 reference

13 August 2017

1 reference